Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intralesional rituximab in recalcitrant pemphigus vulgaris lesions
IRCT20141209020250N3Phase 2Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Aug 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, single-arm trial of rituximab in pemphigus vulgaris (PV), sponsored by Tehran University of Medical Sciences. Started Aug 2018; status: completed.
02
Drugs
rituximab
03
Conditions
pemphigus vulgaris (PV)
Beyond the preview
Go deeper on IRCT20141209020250N3.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20141209020250N3.